Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 18Metastatic Castration-resistant Prostate Cancer 3Prostatic Neoplasms, Castration-Resistant 2Neoplasms 2Metastatic Castration Resistant Prostate Cancer 2Prostate Cancer Metastatic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistent Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Breast Neoplasms 1Abiraterone Acetate 1

Interventions

Cyclophosphamide 149Docetaxel 139Paclitaxel 127Trastuzumab 120Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × Abiraterone Acetate × Clear all
NCT01517802 2022-05-10

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Janssen Research & Development, LLC

Phase 3 Completed
32 enrolled 7 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡